Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-16T13:18:37.039Z Has data issue: false hasContentIssue false

Practical issues in conducting multinational, multicenter trials managed by Contract Research Organisations

Published online by Cambridge University Press:  16 April 2020

M Placchi*
Affiliation:
UCB SA Pharma Sector, Research & Development, Chemin du Foriest, B-1420Braine-l’Alleud, Belgium
Get access

Extract

Large multinational, multicenter trials are increasingly being performed during Phase III of the clinical development of a psychotropic drug to demonstrate the efficacy of the new therapeutic agent in the shortest possible time. The testing of the new drug therapy under a common protocol, foreseeing the combination of clinical data collected across countries for a joint evaluation, is becoming more frequent in drug development. Usually, Sponsors use the services of Contract Research Organisations (CROs) to undertake and manage such large multinational, multicenter trials.

The Sponsor who is setting up large definitive CRO-managed studies with psychotropics may anticipate to encounter issues along the following lines: Psychiatric Practice, Organization and Logistics, Data Integration and Manpower.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Submit a response

Comments

No Comments have been published for this article.